Crispr Reports Its First Profit In 10 Quarters, And Shares Fly Out Of A Buy Zone

Crispr Therapeutics reported its first profit in 10 quarters on Wednesday, and CRSP stock popped before sinking into the red. This is the company’s first earnings report following the historic approval of Casgevy, its gene-edited treatment for sickle cell disease and beta thalassemia. During the quarter ended Dec. 31, Crispr earned $1.10 per share, flipping from a year-earlier loss of $1.41.